ASKA Pharmaceutical Holdings Co.,Ltd.
Notice Regarding Transition to a Company with an Audit and Supervisory Committee
Asuka Pharmaceutical Holdings Co., Ltd. has resolved to transition to a company with an audit and supervisory committee, subject to approval at the 5th Annual General Meeting of Shareholders scheduled for June 24, 2026.
Key Figures
- Scheduled Transition Date: June 24, 2026 (Date of the 5th Annual General Meeting of Shareholders)
- Audit and Supervisory Committee Composition: Majority of the members are outside directors
- Delegation of Board Authority: Decision-making authority regarding business execution delegated to directors
AI要約
Purpose of Transition to a Company with an Audit and Supervisory Committee
Asuka Pharmaceutical Holdings Co., Ltd. has resolved to transition to a company with an audit and supervisory committee with the aim of enhancing management transparency and accelerating decision-making. The audit and supervisory committee will consist of a majority of outside directors, tasked with auditing and supervising the legality and appropriateness of business execution. Furthermore, decision-making authority regarding business execution by the board of directors will be delegated to the directors to promote prompt management decisions and execution.
Timing of the Transition and Future Plans
The transition to a company with an audit and supervisory committee is contingent upon the approval of amendments to the Articles of Incorporation at the 5th Annual General Meeting of Shareholders scheduled for June 24, 2026. Details regarding the amendments to the Articles of Incorporation and executive appointments will be announced once finalized.
